Condition (MeSH)
Guillain-Barre Syndrome
ClinicalTrials.gov lists 95 trials for Guillain-Barre Syndrome or a narrower condition beneath it. Novartis Vaccines has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
95 of the 95 trials are tagged with Guillain-Barre Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Guillain-Barre Syndrome trials start? (22)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 10
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 7 |
| 2025 | 10 |
| 2024 | 10 |
| 2023 | 7 |
| 2022 | 8 |
| 2021 | 6 |
| 2020 | 5 |
| 2019 | 6 |
| 2018 | 2 |
| 2017 | 1 |
Showing 10 of 22 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 7 trials starting in 2026 and about 8 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 31 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 17 months across 43 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Guillain-Barre Syndrome trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 8 |
| Phase 1/2 | 1 |
| Phase 2 | 7 |
| Phase 2/3 | 2 |
| Phase 3 | 6 |
| Phase 4 | 2 |
| Not applicable | 20 |
| Observational | 49 |
How many Guillain-Barre Syndrome trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 10 |
| Recruiting | 12 |
| Enrolling by invitation | 3 |
| Active, not recruiting | 1 |
| Completed | 40 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Guillain-Barre Syndrome trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Novartis Vaccines | 4 |
| Annexon, Inc. | 3 |
| Alexion Pharmaceuticals, Inc. | 1 |
Which drugs are being tested for Guillain-Barre Syndrome? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Immunoglobulin | 6 |
| Efgartigimod | 3 |
| ANX005 | 3 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Globulin, Immune | 2 |
| Group B streptococcus (GBS) vaccine | 2 |
| Plasma Exchange | 2 |
| Intravenous Immunoglobulins, Human | 1 |
| Lumbar puncture | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Guillain-Barre Syndrome trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Appendicitis | 5 | 1 |
| Abortion Spontaneous | 3 | 1 |
| Neuropathy peripheral | 3 | 1 |
| Pneumonia | 3 | 2 |
| Depression | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Guillain-Barre Syndrome? (106)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Characteristics of ventilator weaning in patients intubated for Guillain-Barré syndrome or myasthenia gravis: a nationwide multicenter study. | Intensive care medicine | 2025 | Yes |
| Landscape of Guillain-Barré Syndrome Interventional Clinical Trials. | Journal of clinical neuromuscular disease | 2023 | Yes |
| Early electrophysiological study variants and their relationship with clinical presentation and outcomes of patients with Guillain-Barré syndrome. | Scientific reports | 2023 | Yes |
| Predicting Outcome in Guillain-Barré Syndrome: International Validation of the Modified Erasmus GBS Outcome Score. | Neurology | 2022 | Yes |
| Guillain-Barré syndrome: expanding the concept of molecular mimicry. | Trends in immunology | 2022 | Yes |
Showing 5 of 106 publications.
Prevalence (21)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Guillain-Barré syndrome | Annual incidence | 1-9 / 100 000 | United States | US | Unspecified |
| Guillain-Barré syndrome | Annual incidence | 1-9 / 100 000 | United States | US | Exact |
| Guillain-Barré syndrome | Annual incidence | 1-9 / 100 000 | United States | US | Exact |
| Guillain-Barré syndrome | Annual incidence | 1-9 / 100 000 | Europe | Not stated | Exact |
| Guillain-Barré syndrome | Point prevalence | 1-5 / 10 000 | Denmark | Not stated | Exact |
Showing 5 of 21 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Guillain-Barré syndrome | 2103 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Guillain-Barré syndrome | 2103 | Exact | Orphadata Science knowledge files, Product 1 |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.